NCT04511923

Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury

Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: University College Hospital Galway · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators present a randomised open label phase Ib/IIa trial of nebulised unfractionated heparin to evaluate the effect of nebulised unfractionated heparin on the procoagulant response in ICU patients with SARS-CoV-2 requiring advanced respiratory support. As this is one of the first studies of nebulised heparin in COVID 19 lung disease the investigators will assess safety as a co-primary outcome.

Conditions

• Covid19
• ARDS, Human
• Lung Injury, Acute
• Ventilation Perfusion Mismatch

Interventions

Type	Name	Description
DRUG	Nebulised heparin	Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days

Timeline

• Start date: 2020-12-23
• Primary completion: 2021-12-31
• Completion: 2022-02-28
• First posted: 2020-08-13
• Last updated: 2024-07-24

Locations

1 site across 1 country: Ireland